Xiaobo He1, Ting Zhou1, Yunpeng Yang1, Shaodong Hong1, Jianhua Zhan1, Zhihuang Hu1, Wenfeng Fang1, Tao Qin1, Yuxiang Ma1, Yuanyuan Zhao1, Zhibin Cheng2, Yan Huang1, Hongyun Zhao1, Guangwei Yang2, Li Zhang3. 1. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 2. Department of Oncological Radiotherapy, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. 3. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: zhangli6@mail.sysu.edu.cn.
Abstract
UNLABELLED: This report is the first to use the value of the Advanced Lung Cancer Inflammation Index (ALI) to predict the overall survival in patients with small-cell lung cancer. We enrolled 365 patients who were eligible for analysis and found that lower ALI was significantly associated with worse overall survival in small-cell lung cancer patients. The results showed that evaluation using ALI could authenticate the patients with poor prognosis and be a useful prognostic marker in clinical practice. BACKGROUND: A recent study indicated that the Advanced Lung Cancer Inflammation Index (ALI) could predict overall survival (OS) in patients with non-small-cell lung cancer. However, the prognostic value in small-cell lung cancer (SCLC) has not been studied. Therefore, the aim of this study was to explore the relationship between ALI and the prognosis of SCLC. PATIENTS AND METHODS: We screened 460 patients who were diagnosed with SCLC from June 2006 to December 2011 in Sun Yat-Sen University Cancer Center. Data acquisition was through patients' medical information, and blood results recorded at the time of diagnosis. ALI was calculated as the formula: body mass index × serum albumin/neutrophil-lymphocyte ratio. RESULTS: In total, 365 patients were enrolled in this study. Patients were allocated to 2 groups: ALI < 19.5 (n = 60) and ALI ≥ 19.5 (n = 305). For patients with ALI < 19.5 and ≥ 19.5, the median OS was 10.97 and 20.14 months, respectively (P < .001). On multivariate analysis, clinical stage (P < .001), performance status (P = .001), lactate dehydrogenase (P < .001), and ALI (P = .005) were all independent prognostic factors for OS. CONCLUSION: The results of this study demonstrated that lower ALI was significantly associated with worse OS in SCLC patients. The evaluation of ALI could authenticate the patients with poor prognosis and be a useful prognostic marker in clinical practice.
UNLABELLED: This report is the first to use the value of the Advanced Lung Cancer Inflammation Index (ALI) to predict the overall survival in patients with small-cell lung cancer. We enrolled 365 patients who were eligible for analysis and found that lower ALI was significantly associated with worse overall survival in small-cell lung cancerpatients. The results showed that evaluation using ALI could authenticate the patients with poor prognosis and be a useful prognostic marker in clinical practice. BACKGROUND: A recent study indicated that the Advanced Lung Cancer Inflammation Index (ALI) could predict overall survival (OS) in patients with non-small-cell lung cancer. However, the prognostic value in small-cell lung cancer (SCLC) has not been studied. Therefore, the aim of this study was to explore the relationship between ALI and the prognosis of SCLC. PATIENTS AND METHODS: We screened 460 patients who were diagnosed with SCLC from June 2006 to December 2011 in Sun Yat-Sen University Cancer Center. Data acquisition was through patients' medical information, and blood results recorded at the time of diagnosis. ALI was calculated as the formula: body mass index × serum albumin/neutrophil-lymphocyte ratio. RESULTS: In total, 365 patients were enrolled in this study. Patients were allocated to 2 groups: ALI < 19.5 (n = 60) and ALI ≥ 19.5 (n = 305). For patients with ALI < 19.5 and ≥ 19.5, the median OS was 10.97 and 20.14 months, respectively (P < .001). On multivariate analysis, clinical stage (P < .001), performance status (P = .001), lactate dehydrogenase (P < .001), and ALI (P = .005) were all independent prognostic factors for OS. CONCLUSION: The results of this study demonstrated that lower ALI was significantly associated with worse OS in SCLCpatients. The evaluation of ALI could authenticate the patients with poor prognosis and be a useful prognostic marker in clinical practice.
Authors: Eun Young Kim; Young Saing Kim; Ja-Young Seo; Inkeun Park; Hee Kyung Ahn; Yu Mi Jeong; Jeong Ho Kim; Nambeom Kim Journal: PLoS One Date: 2016-08-18 Impact factor: 3.240
Authors: Eun Young Kim; Nambeom Kim; Young Saing Kim; Ja-Young Seo; Inkeun Park; Hee Kyung Ahn; Yu Mi Jeong; Jeong Ho Kim Journal: PLoS One Date: 2016-10-05 Impact factor: 3.240
Authors: Nigar Dirican; Ahmet Dirican; Ceyda Anar; Sule Atalay; Onder Ozturk; Ahmet Bircan; Ahmet Akkaya; Munire Cakir Journal: Asian Pac J Cancer Prev Date: 2016-12-01
Authors: Erkan Topkan; Huseyin Mertsoylu; Yurday Ozdemir; Ahmet Sezer; Ahmet Kucuk; Ali Ayberk Besen; Ozgur Ozyilkan; Ugur Selek Journal: Cancer Manag Res Date: 2019-10-07 Impact factor: 3.989
Authors: Dominik Andreas Barth; Carina Brenner; Jakob Michael Riedl; Felix Prinz; Eva Valentina Klocker; Konstantin Schlick; Peter Kornprat; Karoline Lackner; Herbert Stöger; Michael Stotz; Armin Gerger; Martin Pichler Journal: Cancer Med Date: 2020-06-14 Impact factor: 4.711